Latest News

Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer.

Second interim analysis results from the phase 3 RUBY trial demonstrated that the addition of dostarlimab to chemotherapy improved overall survival among patients with primary advanced or recurrent endometrial cancer.

Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.

Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.

Results from the phase 3 IMpassion132 study demonstrated that the addition of atezolizumab to chemotherapy did not improve overall survival among patients with early relapsing unresectable advanced or metastatic triple-negative breast cancer.

According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.

Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.

Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...

According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...